Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004221 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00004221 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 12 participants.
The verdict
NCT00004221, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Filgrastim
- PROCEDURE Peripheral Blood Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1999-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004221
The ClinicalTrials.gov registry entry for NCT00004221 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00004221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004221 about?
NCT00004221 is a clinical study titled "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer". Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Co...
What is the current status of trial NCT00004221?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 1999-11.
What interventions are being tested in trial NCT00004221?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), Filgrastim (BIOLOGICAL), Peripheral Blood Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00004221?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.